Our doctors and researchers are leaders in developing chimeric antigen receptor (CAR) T-cell immunotherapies to treat children and young adults with relapsed or refractory cancers. 

Immunotherapy is an experimental new cancer treatment that uses the immune system to fight disease. Read more about how T-cell immunotherapy works.

CAR T-Cell Therapy for Solid Tumors: STRIvE-01 

A Food and Drug Administration-authorized clinical trial at Seattle Children’s is testing CAR T-cell therapy in children and young adults with relapsed or refractory solid tumors who are not likely to survive with standard treatments.

The trial is called STRIvE-01. In this trial, the patient’s own T cells are reprogrammed to recognize and target the protein EGFR, which is expressed by many childhood solid tumors, including sarcomas, kidney tumors and neuroblastoma. 

The study began in August 2018 and is currently enrolling patients. 

Contact Us 

For more information, call 206-987-2106 or send us an email.

What is the goal of the STRIvE-01 study? 

STRIvE-01 is a phase 1 trial. Phase 1 trials focus on finding out how much of a therapy to give, how to give it, how often to give it and when side effects occur. Through the STRIvE-01 study, researchers are working to answer these questions: 

  • Is T-cell therapy safe to give to children and young adults with relapsed or refractory solid tumors?
  • What is the best dose of CAR T cells for children and young adults with solid tumors?
  • Does T-cell therapy work against solid tumors? 

Who can join STRIvE-01? 

This study is for children and young adults who:

  • Have relapsed or refractory solid tumors that express the protein EGFR 
  • Are ages 1 to 26 years old 

Researchers use many other factors to decide whether a patient can take part in a study (inclusion criteria) or cannot take part (exclusion criteria). The study team at Seattle Children’s can explain what these factors mean for you or your child.

Who is leading this trial? 

Albert is a doctor in the Cancer and Blood Disorders Center at Seattle Children’s Hospital and an investigator in the Ben Towne Center for Childhood Cancer Research at Seattle Children’s Research Institute.

T-cell trials at Seattle Children’s use methods developed by Dr. Michael Jensen of the Ben Towne Center for Childhood Cancer Research and Dr. Julie Park of the Seattle Children’s Research Institute. 

Are there studies for other childhood cancers?

STRIvE is one of our many T-cell immunotherapy trials focused on using the immune system to offer better treatment options for children and young adults with cancers, including: 

Contact Us

For more information, call 206-987-2106 or send us an email

Learn More 

Updated August 2018.

New Cure. New Hope.

Strong Against Cancer logoThrough our Strong Against Cancer initiative, we’re leading the fight against childhood cancer with immunotherapy. Learn how you can get involved.